PBGM01
Infantile GM1 Gangliosidosis
Phase 1/2Active (Imagine-1 study)
Key Facts
Indication
Infantile GM1 Gangliosidosis
Phase
Phase 1/2
Status
Active (Imagine-1 study)
Company
About Passage Bio
Passage Bio is dedicated to fulfilling the promise of genetic medicine by developing transformative therapies for people with devastating CNS diseases. The company leverages its expertise in AAV vector engineering and delivery to target monogenic neurodegenerative disorders with high unmet need. With two lead programs in Phase 1/2 clinical trials and a strategic collaboration with the University of Pennsylvania's Gene Therapy Program, Passage Bio is positioned at the forefront of CNS gene therapy. Their mission centers on turning disbelief into belief and transforming the lives of patients and their families.
View full company profile